The U.S. psoriasis treatment market for Biologics and Biosimilars was estimated at $6.6bn in 2016 is projected to almost double during the forecast period to reach $12.9bn in 2021 driven by safety and efficacy improvements of the new generation biologics.
The psoriasis treatment market is dominated by topical agents and photo therapy for the non-severe forms (mainly corticosteroids), but mild to severe forms are treated with systemic agents. The psoriasis treatment market is dominated by topical agents and photo therapy for the non-severe forms (mainly corticosteroids), but mild to severe forms are treated with systemic agents.
Get a Sample Report@ https://www.wiseguyreports.com/sample-request/2395209-the-future-of-the-u-s-biologics-and-biosimilars-treatment-market-for-psoriasis
For more information or any query mail at sales@wiseguyreports.com
Driven by improved efficacy, the first group of anti TNF treatments led by Enbrel, Humira and Remicade made strong penetration into the psoriasis market. However the emergence of the IL-17 inhibitor class driven by Novartis’ Cosentyx and Eli Lilly’s Talz have set a new benchmark for efficacy in moderate to severe psoriasis treatment with potential for safety improvement in comparison to the anti TNF drugs given their greater specificity in immune Suppression. MP Advisors expect the TNF class of drugs to lose share to the newer brands with improved clinical profiles in Psoriasis.
The market growth in psoriasis is driven by an upsurge in demand from new therapies in moderate to severe patient population which overshadows reduced pricing of branded TNF-α inhibitor and recent biosimilar launches. The psoriasis treatment market is facing increasing competitive pressure from a wave of biosimilar launches such as biosimilars of Janssen’s Remicade, and Amgen’s Enbrel with the impact of the headwinds expected to be more pronounced in the next few years.
Stelara has been an important growth driver of Janssen’s immunology franchise in recent years, with overall global sales doubling from $1.5bn in 2013 to more than $3.2bn in 2016. However Stelara has started to face steeper competition from the IL-17 drug class. A new head-to-head study report IL-17 products to demonstrate superior efficacy to Stelara for psoriasis.
Table Of Contents – Major Key Points
1. Psoriasis Market Overview 9
1.1. Disease background 9
1.2. Types of psoriasis 10
1.2.1. Plaque psoriasis 11
1.2.2. Guttate psoriasis 11
1.2.3. Inverse (flexural) psoriasis 11
1.2.4. Pustular psoriasis 11
1.2.5. Erythrodermic psoriasis 12
1.3. Pathophysiology 12
1.4. Etiology 12
1.4.1. Environmental factors 12
1.4.2. Genetic factors 12
1.4.3. Immunologic factors 14
1.5. Risk factors and co-morbidities 16
1.6. Epidemiology 16
1.7. Treatment options 17
1.7.1. Phototherapy 18
1.7.2. Topical treatments 18
1.7.3. Conventional systemic agents 18
1.7.4. Other systemic drugs 18
1.7.5. Biologics 18
1.8. Treatment Guidelines 19
1.8.1. Mild to moderate Psoriasis 22
1.8.2. Moderate Psoriasis 22
1.8.3. Moderate –to–severe psoriasis 22
1.8.4. Severe psoriasis 22
2. Psoriasis Treatment Market for Biologics 23
2.1. Introduction and Market Overview 23
2.2. Revenue Analysis for Biologics in the U.S. 30
2.3. Key marketed products for psoriasis treatment 33
2.3.1. Remicade (infliximab; Janssen) 38
2.3.2. Humira (adalimumab; AbbVie) 42
2.3.3. Stelara (ustekinumab; Janssen) 46
2.3.4. Cosentyx (secukinumab; Novartis) 50
2.3.5. Taltz (ixekizumab; Lilly) 55
2.3.6. Siliq (brodalumab; Valeant) 59
2.3.7. Tremfya (guselkumab; Janssen) 62
2.4. Key pipeline products for psoriasis treatment 65
2.4.1. Tildrakizumab; Merck / Sun Pharma 66
2.4.2. Cimzia (certolizumab pegol; UCB/Dermira Pharmaceuticals) 68
2.4.3. Risankizumab; AbbVie/Boehringer Ingelheim 70
2.5. Growth Drivers and Resistors for Biologics 71
2.5.1. Growth Drivers: 71
2.5.2. Resistors 73
2.6. Competitive Landscape ‒ Approved Products 75
2.7. Competitive Landscape ‒ Pipeline Products 77
3. Psoriasis Market for Biosimilars 79
3.1. Introduction and Market Overview 79
3.2. Approved biosimilars 79
3.2.1. Approved biosimilars in the U.S. 79
3.2.2. Revenue Analysis for Biosimilars in U.S. 81
3.2.3. Approved biosimilars in the EU 81
3.3. Pipeline Analysis 83
3.3.1. Clinical development ‒ Humira (adalimumab) biosimilars 84
3.3.2. Clinical development ‒ Enbrel (etanercept) biosimilars 84
Continue…….
Buy 1-User PDF @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=2395209
For more information or any query mail at sales@wiseguyreports.com
ABOUT US:
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.
Media Contact
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: sales@wiseguyreports.com
Phone: +1 646 845 9349, +44 208 133 9349
City: Pune
State: Maharashtra
Country: India
Website: www.wiseguyreports.com